Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FPR2 | P25090 | 5/20 | 0.62 |
| ▸ | CA1 | P00915 | 2/20 | 0.52 |
| ▸ | CA2 | P00918 | 2/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.51 |
| ▸ | FOLH1 | Q04609 | 7/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4599005 | 1.00 | FPR2 (0.62) | FPR2CA1CA2EPHX2FOLH1 | |
| SCHEMBL4738073 | 0.88 | SMN1; SMN2 (0.53) | FPR2CA1CA2FOLH1SMN1; SMN2 | |
| SCHEMBL4738077 | 0.88 | SMN1; SMN2 (0.53) | FPR2CA1CA2FOLH1SMN1; SMN2 | |
| SCHEMBL4600141 | 0.86 | FOLH1 (0.63) | FPR2CA1CA2FOLH1 | |
| SCHEMBL4600137 | 0.86 | FOLH1 (0.63) | FPR2CA1CA2FOLH1 | |
| SCHEMBL4600160 | 0.84 | CA1 (0.56) | FPR2CA1CA2FOLH1 | |
| SCHEMBL4600162 | 0.84 | CA1 (0.56) | FPR2CA1CA2FOLH1 | |
| SCHEMBL28216420 | 0.84 | FOLH1 (0.61) | FPR2CA1CA2FOLH1KMT2A | |
| SCHEMBL4888941 | 0.83 | CA1 (0.45) | FPR2CA1CA2FOLH1SMN1; SMN2 | |
| SCHEMBL4888928 | 0.83 | CA1 (0.45) | FPR2CA1CA2FOLH1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | FPR2 3112/4885CA1 4464/4885CA2 4735/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | FPR2 3738/4885CA1 4583/4885CA2 4185/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.